source
- UniQure files FDA priority review request for Huntington’s gene therapy AMT-130UniQure, a Dutch biotech, announced on Wednesday that it has submitted applications to the U.S. Food and Drug Administration seeking a priority review for its gene therapy AMT-130, which targets th…
- UniQure submits FDA and UK applications for first Huntington’s disease gene therapyUniQure has filed a biologics license application (BLA) with the U.S. FDA and a separate submission with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its experimental gene…